亲爱的研友该休息了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!身体可是革命的本钱,早点休息,好梦!

Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1/2 clinical trials

医学 trk受体 临床试验 临床终点 肿瘤科 人口 内科学 外科 合并分析 儿科 置信区间 神经营养素 环境卫生 受体
作者
David S. Hong,Steven G. DuBois,Shivaani Kummar,Anna F. Farago,Catherine Michelle Albert,Kristoffer Staal Rohrberg,Cornelis Martinus van Tilburg,Ramamoorthy Nagasubramanian,Jordan D. Berlin,Noah C. Federman,Leo Mascarenhas,Birgit Geoerger,Afshin Dowlati,Alberto S. Pappo,Stefan Bielack,François Doz,Ray McDermott,Jyoti D. Patel,Russell J. Schilder,Makoto Tahara
出处
期刊:Lancet Oncology [Elsevier BV]
卷期号:21 (4): 531-540 被引量:1083
标识
DOI:10.1016/s1470-2045(19)30856-3
摘要

Summary

Background

The selective TRK inhibitor larotrectinib was approved for paediatric and adult patients with advanced TRK fusion-positive solid tumours based on a primary analysis set of 55 patients. The aim of our analysis was to explore the efficacy and long-term safety of larotrectinib in a larger population of patients with TRK fusion-positive solid tumours.

Methods

Patients were enrolled and treated in a phase 1 adult, a phase 1/2 paediatric, or a phase 2 adolescent and adult trial. Some eligibility criteria differed between these studies. For this pooled analysis, eligible patients were aged 1 month or older, with a locally advanced or metastatic non-CNS primary, TRK fusion-positive solid tumour, who had received standard therapy previously if available. This analysis set includes the 55 patients on which approval of larotrectinib was based. Larotrectinib was administered orally (capsule or liquid formulation), on a continuous 28-day schedule, to adults mostly at a dose of 100 mg twice daily, and to paediatric patients mostly at a dose of 100 mg/m2 (maximum of 100 mg) twice daily. The primary endpoint was objective response as assessed by local investigators in an intention-to-treat analysis. Contributing trials are registered with ClinicalTrials.gov, NCT02122913 (active not recruiting), NCT02637687 (recruiting), and NCT02576431 (recruiting).

Findings

Between May 1, 2014, and Feb 19, 2019, 159 patients with TRK fusion-positive cancer were enrolled and treated with larotrectinib. Ages ranged from less than 1 month to 84 years. The proportion of patients with an objective response according to investigator assessment was 121 (79%, 95% CI 72–85) of 153 evaluable patients, with 24 (16%) having complete responses. In a safety population of 260 patients treated regardless of TRK fusion status, the most common grade 3 or 4 larotrectinib-related adverse events were increased alanine aminotransferase (eight [3%] of 260 patients), anaemia (six, 2%), and decreased neutrophil count (five [2%]). The most common larotrectinib-related serious adverse events were increased alanine aminotransferase (two [<1%] of 260 patients), increased aspartate aminotransferase (two [<1%]), and nausea (two [<1%]). No treatment-related deaths occurred.

Interpretation

These data confirm that TRK fusions define a unique molecular subgroup of advanced solid tumours for which larotrectinib is highly active. Safety data indicate that long-term administration of larotrectinib is feasible.

Funding

Bayer and Loxo Oncology.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
纯情的阁发布了新的文献求助30
1秒前
纯情的阁发布了新的文献求助10
1秒前
纯情的阁发布了新的文献求助30
1秒前
纯情的阁发布了新的文献求助10
1秒前
纯情的阁发布了新的文献求助30
4秒前
纯情的阁发布了新的文献求助10
4秒前
纯情的阁发布了新的文献求助30
4秒前
纯情的阁发布了新的文献求助10
4秒前
纯情的阁发布了新的文献求助30
4秒前
12秒前
17秒前
17秒前
null的应助被科研通管家采纳,获得10
17秒前
null的应助被科研通管家采纳,获得20
17秒前
18秒前
molihuakai的应助被科研通管家采纳,获得10
18秒前
小二郎的应助被科研通管家采纳,获得10
18秒前
18秒前
23秒前
31秒前
车访枫发布了新的文献求助10
34秒前
34秒前
Yeung完成签到,获得积分10
38秒前
h11的应助被Younger采纳,获得10
43秒前
Accepted完成签到 ,获得积分10
46秒前
50秒前
义气慕梅完成签到,获得积分10
51秒前
Younger发布了新的文献求助10
53秒前
58秒前
自由的青亦完成签到,获得积分10
58秒前
Juni发布了新的文献求助10
59秒前
1分钟前
方悦发布了新的文献求助10
1分钟前
顺心鼠标完成签到,获得积分10
1分钟前
Tnapo完成签到 ,获得积分10
1分钟前
1分钟前
林xq完成签到 ,获得积分10
1分钟前
1分钟前
bkagyin的应助被小黑桃采纳,获得10
1分钟前
1分钟前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1500
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
What Else Can I Tell You?: A Pragmatic Study of English Rhetorical Questions as Discursive and Argumentative Acts 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8158669
求助须知:如何正确求助?哪些是违规求助? 9554462
关于积分的说明 21719186
捐赠科研通 7748228
什么是DOI,文献DOI怎么找? 3427070
关于科研通互助平台的介绍 2551942
邀请新用户注册赠送积分活动 2471308